628 related articles for article (PubMed ID: 33516133)
1. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
2. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis.
Piasecka-Stryczyńska K; Kaczyński Ł; Rolka M; Homa M; Staśkiewicz W; Paczwa P; Wójcik R; Kaczor MP; Rejdak K
Neurol Neurochir Pol; 2022; 56(6):480-489. PubMed ID: 36421066
[TBL] [Abstract][Full Text] [Related]
3. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
[TBL] [Abstract][Full Text] [Related]
4. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
J Neurol; 2020 Jul; 267(7):2090-2100. PubMed ID: 32246251
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
[TBL] [Abstract][Full Text] [Related]
6. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
7. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
9. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
[No Abstract] [Full Text] [Related]
10. Comparative effectiveness of dimethyl fumarate in multiple sclerosis.
Bosco-Lévy P; Debouverie M; Brochet B; Guillemin F; Louapre C; Maillart E; Heinzlef O; Lignot S; Diez P; Abouelfath A; Lassalle R; Blin P; Droz-Perroteau C
Br J Clin Pharmacol; 2022 Mar; 88(3):1268-1278. PubMed ID: 34505304
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri D; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H
Mult Scler; 2023 Feb; 29(2):221-235. PubMed ID: 36433775
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Keller B; Jack D; Vermersch P
Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
[TBL] [Abstract][Full Text] [Related]
15. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
Alroughani R; Al-Hashel J; Ahmed SF
Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
17. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
Giovannoni G; Singer BA; Issard D; Jack D; Vermersch P
Mult Scler; 2022 Jul; 28(8):1219-1228. PubMed ID: 34634968
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
Pinheiro B; Guerreiro R; Costa J; Miguel LS
J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
[No Abstract] [Full Text] [Related]
19. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Lambe T; Duarte R; Mahon J; Nevitt S; Greenhalgh J; Boland A; Beale S; Kotas E; McEntee J; Pomeroy I
Pharmacoeconomics; 2019 Mar; 37(3):345-357. PubMed ID: 30328051
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
